CareDx Inc will report its third quarter 2026 financial results after market close on Thursday, October 29, 2026. The precision medicine diagnostics company plans to host a webcast and conference call later that day.

The live conference call is scheduled for 1:30 pm PT / 4:30 pm ET. Investors and analysts can access a live and archived webcast via the Events & Presentations section of the company’s Investor Relations website. Telephone participation requires prior registration, which provides a dial-in number and unique PIN upon completion.

Company Profile

CareDx operates as a leading precision medicine diagnostics company focused on transplant, specialty oncology, and cell therapy sectors. The company utilizes non-invasive longitudinal molecular biomarker testing, digital health solutions, and patient support systems to improve patient outcomes.

CareDx, Inc. (NASDAQ: CDNA), a precision medicine diagnostics company focused on transplant, specialty oncology, and cell therapy, awarded 15,822 shares of common stock restricted stock units (RSUs) to James McNally on July 30, 2026. The equity grants were issued as an inducement material to Mr. McNally’s appointment as the company’s newly appointed Executive Advisor. This move aligns executive compensation with long-term shareholder value while adhering to strict exchange listing requirements for non-board-approved equity awards.

The RSU awards were granted pursuant to CareDx’s 2025 Inducement Equity Incentive Plan. The issuance complies with Nasdaq Listing Rule 5635(c)(4), which permits companies to grant equity awards to new employees or advisors without prior shareholder approval if the awards are an inducement material to the commencement of employment or service.

Vesting Schedule

The vesting of the RSUs is tied to Mr. McNally’s continued service with CareDx through specific dates. The structure splits the total award evenly across two milestones:

CareDx disclosed these details to maintain transparency with investors regarding equity dilution and executive compensation practices. The company operates at the intersection of digital health and molecular biomarker testing, aiming to improve patient outcomes through non-invasive longitudinal monitoring.

What the Numbers Show

The grant of 15,822 RSUs represents a targeted retention strategy for a senior advisory role rather than broad-based employee compensation. By structuring the vesting over approximately 18 months, CareDx ensures that the advisor remains engaged through critical operational periods. The reliance on Nasdaq Rule 5635(c)(4) indicates that this award was not part of the annual shareholder-approved equity pool, highlighting the company’s flexibility in securing specialized leadership talent outside standard board cycles.